Clinical Trials in Pennsylvania

Showing 12641-12660 of 16,895 trials

AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)

NCT01937195

The study will test a hypothesis that the AccuCath™ System will have a higher rate of successful first attempt peripheral intravenous (PIV) placement, higher completion of therapy, fewer complications, longer dwell times, and higher user satisfaction compared to Conventional IV Catheters.

Vascular Access Complication

C. R. Bard95 participantsStarted Apr 2013

Lewisburg, Pennsylvania, United States

COMPLETEDPhase 336 miles

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459

The purpose of this study is to evaluate the safety, tolerability and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe, stable chronic obstructive pulmonary disease. The study will be 56 weeks in duration; a 2-week rin-in period, a 52-week treatment period and a 2-week follow up phone call. All patients will be randomized to one of two doses of aclidinium bromide.

Chronic Obstructive Pulmonary Disease

AstraZeneca605 participantsStarted Nov 2009

Birmingham, Alabama, United States • Mobile, Alabama, United States • Scottsdale, Arizona, United States +110 more locations

AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

Find Trials by Condition in Pennsylvania

Adaptation Processes in School-Based Substance Abuse Programs

Adaptation Processes in School-based Substance Abuse Prevention

Gamma Vacuum Foil (GVF) Versus Cross-linked Polyethylene in Total Knee Arthroplasty Study

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

Phase II Proof of Concept Study in Uncomplicated UTI

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC

Staccato Loxapine in Migraine (Out Patient)

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)